公开(公告)号：US20230125739A1

公开(公告)日：2023-04-27

申请号：US17984069

申请日：2022-11-09

Applicant: FORMA Therapeutics, Inc.

Inventor： Jian Lin ,  Anna Ericsson ,  Ann-Marie Campbell ,  Gary Gustafson ,  Zhongguo Wang ,  R. Bruce Diebold ,  Susan Ashwell ,  David R. Lancia, JR. ,  Justin Andrew Caravella ,  Wei Lu

IPC: C07D401/12 ,  C07D401/14 ,  C07D471/04 ,  A61P35/00

Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where A, U, W1, W2, W3, R1-R6, and R9 are described herein.

公开(公告)号：US20220304987A1

公开(公告)日：2022-09-29

申请号：US17698505

申请日：2022-03-18

Applicant: FORMA Therapeutics, Inc.

Inventor： Anna Ericsson ,  Neal Green ,  Gary Gustafson ,  David R. Lancia, JR. ,  Gary Marshall ,  Lorna Mitchell ,  David Richard ,  Zhongguo Wang ,  Sanjeev Forsyth ,  Patrick F. Kelly ,  Madhu Mondal ,  Maria Ribadeneira ,  Patricia Schroeder

IPC: A61K31/436 ,  A61P9/00

Abstract: The compound (S)-1-(5-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)sulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-3-hydroxy-2-phenylpropan-1-one, or a pharmaceutically acceptable salt thereof, is useful to increase the affinity of hemoglobin for oxygen. Methods and compositions for the treatment of a hemoglobinopathies are provided herein, including certain pharmaceutical compositions for activating PKR.

公开(公告)号：US11161848B2

公开(公告)日：2021-11-02

申请号：US16540327

申请日：2019-08-14

Applicant: FORMA Therapeutics, Inc.

Inventor： Alexandre Joseph Buckmelter ,  Stephanos Ioannidis ,  Bruce Follows ,  Gary Gustafson ,  Minghua Wang ,  Justin A. Caravella ,  Zhongguo Wang ,  Edward L. Fritzen ,  Jian Lin

IPC: C07D473/00 ,  A61K31/522

Abstract: The application relates to inhibitors of USP1 useful in the treatment of cancers, and other USP1 associated diseases and disorders, having the Formula: where R1, R2, R3, R3′, R4, R5, X1, X2, X3, X4, and n are described herein.

公开(公告)号：US20210078973A1

公开(公告)日：2021-03-18

申请号：US17101018

申请日：2020-11-23

Applicant: FORMA Therapeutics, Inc.

Inventor： Jian Lin ,  Anna Ericsson ,  Ann-Marie Campbell ,  Gary Gustafson ,  Zhongguo Wang ,  R. Bruce Diebold ,  Susan Ashwell ,  David R. Lancia, JR. ,  Justin Andrew Caravella ,  Wei Lu

IPC: C07D401/12 ,  C07D401/14 ,  C07D471/04 ,  A61P35/00

Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where A, U, W1, W2, W3, R1-R6, and R9 are described herein.

公开(公告)号：US10550099B2

公开(公告)日：2020-02-04

申请号：US16290328

申请日：2019-03-01

Applicant: FORMA Therapeutics, Inc.

Inventor： Jian Lin ,  Anna Ericsson ,  Ann-Marie Campbell ,  Gary Gustafson ,  Zhongguo Wang ,  R. Bruce Diebold ,  Susan Ashwell ,  David R. Lancia, Jr. ,  Justin Andrew Caravella ,  Wei Lu

IPC: A61K31/506 ,  C07D401/12 ,  C07D405/14 ,  C07D401/14 ,  C07D417/14 ,  C07D413/14 ,  C07D471/04 ,  C07D409/14 ,  C07D403/12

Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where A, B, W1, W2, W3, and R1-R6 are described herein.

公开(公告)号：US20190263778A1

公开(公告)日：2019-08-29

申请号：US16290240

申请日：2019-03-01

Applicant: FORMA Therapeutics, Inc.

Inventor： Jian Lin ,  Anna Ericsson ,  Ann-Marie Campbell ,  Gary Gustafson ,  Zhongguo Wang ,  R. Bruce Diebold ,  Susan Ashwell ,  David R. Lancia, JR. ,  Justin Andrew Caravella ,  Wei Lu

IPC: C07D401/12 ,  C07D471/04 ,  A61P35/00 ,  C07D401/14

Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where A, U, W1, W2, W3, R1-R6, and R9 are described herein.

公开(公告)号：US11649242B2

公开(公告)日：2023-05-16

申请号：US17239364

申请日：2021-04-23

Applicant: FORMA Therapeutics, Inc.

Inventor： Anna Ericsson ,  Neal Green ,  Gary Gustafson ,  Bingsong Han ,  David R. Lancia, Jr. ,  Lorna Mitchell ,  David Richard ,  Tatiana Shelekhin ,  Chase C. Smith ,  Zhongguo Wang ,  Xiaozhang Zheng

IPC: C07D487/04 ,  C07D519/00 ,  A61P7/00 ,  A61K9/00 ,  A61K31/407

CPC classification number: C07D487/04 ,  A61K9/0053 ,  A61K31/407 ,  A61P7/00 ,  C07D519/00

Abstract: The disclosure relates to modulating pyruvate kinase and provides novel chemical compounds useful as activators of PKR, as well as various uses of these compounds. PKR activating compounds are useful in the treatment of diseases and disorders associated with PKR and/or PKM2, such as pyruvate kinase deficiency (PKD), sickle cell disease (SCD), and thalassemia.

公开(公告)号：US20220378756A1

公开(公告)日：2022-12-01

申请号：US17761795

申请日：2020-09-18

Applicant: FORMA Therapeutics, Inc.

Inventor： Anna Ericsson ,  Sanjeev Forsyth ,  Neal Green ,  Gary Gustafson ,  Patrick F. Kelly ,  David R. Lancia, JR. ,  Gary Marshall ,  Lorna Mitchell ,  Madhu Mondal ,  Maria Ribadeneira ,  David Richard ,  Patricia Schroeder ,  Zhongguo Wang

IPC: A61K31/436 ,  A61K9/48 ,  A61K9/00 ,  A61P7/06

Abstract: The compound (S)-1-(5-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)sulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrroll-2(1H)-yl)-3-hydroxy-2-phenylpropan-1-one, or a pharmaceutically acceptable salt thereof, is useful to increase the affinity of hemoglobin for oxygen. Methods and compositions for the treatment of a hemoglobinopathies are provided herein, including certain pharmaceutical compositions for activating PKR.

公开(公告)号：US20220281869A1

公开(公告)日：2022-09-08

申请号：US17490482

申请日：2021-09-30

Applicant: FORMA Therapeutics, Inc.

Inventor： Alexandre Joseph Buckmelter ,  Stephanos Ioannidis ,  Bruce Follows ,  Gary Gustafson ,  Minghua Wang ,  Justin Andrew Caravella ,  Zhongguo Wang ,  Edward L. Fritzen ,  Jian Lin

IPC: C07D473/00 ,  A61K31/522

Abstract: The application relates to inhibitors of USP1 useful in the treatment of cancers, and other USP1 associated diseases and disorders, having the Formula: where R1, R2, R3, R3′, R4, R5, X1, X2, X3, X4, and n are described herein.

公开(公告)号：US10675274B2

公开(公告)日：2020-06-09

申请号：US16576360

申请日：2019-09-19

Applicant: FORMA Therapeutics, Inc.

Inventor： Anna Ericsson ,  Neal Green ,  Gary Gustafson ,  David R. Lancia, Jr. ,  Gary Marshall ,  Lorna Mitchell ,  David Richard ,  Zhongguo Wang

IPC: A61K31/436 ,  C07D487/04

Abstract: This disclosure provides compounds and compositions for activating pyruvate kinase R (PKR) and related methods of manufacturing and using these compounds and compositions.